Advanced Pharmaceutical Formulations with Self-Regulating pH and AI-Driven Optimization
Legal Citation
Summary of the Inventive Concept
This inventive concept envisions a next-generation pharmaceutical composition with a self-regulating pH buffering system and AI-driven optimization for enhanced stability, processability, and personalized medicine.
Background and Problem Solved
The original patent described a pharmaceutical composition comprising an antibody, glycine, acetate buffer, and polysorbate 80. However, this composition may have limitations in terms of pH stability and scalability. The new inventive concept addresses these limitations by introducing a self-regulating pH buffering system and leveraging machine learning algorithms to optimize formulation and administration.
Detailed Description of the Inventive Concept
The advanced pharmaceutical formulation comprises an antibody, glycine, and polysorbate 80, with a self-regulating pH buffering system that maintains a pH between 4.6 and 5.5 without additional buffering agents. The composition is formulated using a machine learning algorithm to optimize stability and processability. Additionally, the composition can be lyophilized and reconstituted on-demand using a portable, automated reconstitution device. The inventive concept also encompasses a method for real-time monitoring of pharmaceutical composition stability using a microfluidic device and a machine learning algorithm to predict degradation patterns. Furthermore, the composition can be tailored to an individual patient's specific needs and administered using a wearable, implantable, or injectable device.
Novelty and Inventive Step
The new claims introduce a paradigm shift in pharmaceutical formulation by incorporating self-regulating pH buffering systems and AI-driven optimization. This enables enhanced stability, processability, and personalized medicine, which are not addressed by the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different pH buffering systems, machine learning algorithms, or reconstitution devices. Variations could also include the incorporation of additional excipients or the use of different administration routes.
Potential Commercial Applications and Market
The advanced pharmaceutical formulation has significant commercial potential in the pharmaceutical industry, particularly in the areas of personalized medicine, biologics, and specialty pharmaceuticals. The market for such formulations is expected to grow significantly in the coming years, driven by the increasing demand for targeted and efficient therapies.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/39591 |
| A | A61 | A61K47/12 |
| A | A61 | A61K47/183 |
| A | A61 | A61K47/26 |
| C | C07 | C07K16/244 |
| C | C07 | C07K2317/76 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically antibody formulation and drug delivery systems, involving protein chemistry, buffer design, and advanced pharmaceutical engineering
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmaceutical sciences or bioengineering, expertise in protein stability, formulation techniques, and familiarity with machine learning applications in drug development
Obviousness Rationale
A PHOSITA would recognize that the PTD's AI-driven optimization and self-regulating pH buffering system represent predictable extensions of existing pharmaceutical formulation strategies. The core composition remains substantially similar to the source patent, with incremental technological enhancements that leverage known techniques in machine learning and microfluidic monitoring. These variations represent standard engineering problem-solving approaches within pharmaceutical development.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,625 |
|---|---|
| Title | Pharmaceutical compositions |
| Assignee(s) | UCB BIOPHARMA SRL |